Dyne Therapeutics Q1 adjusted EPS beats expectations on lower expenses
Dyne Therapeutics Inc DYN | 0.00 |
Overview
US biotech reported Q1 adjusted EPS beat analyst expectations
Q1 net loss slightly missed analyst expectations
R&D expenses fell due to timing of manufacturing batches; G&A rose on launch preparation
Outlook
Dyne expects to submit BLA for z-rostudirsen in DMD in Q2 2026
Company targets potential U.S. launch of z-rostudirsen in Q1 2027, pending approval
Dyne expects to complete enrollment in z-basivarsen ACHIEVE trial in Q2 2026
Result Drivers
R&D EXPENSES - Decrease in R&D expenses was primarily due to timing of manufacturing batches for z-rostudirsen and z-basivarsen
G&A EXPENSES - Increase in G&A expenses was primarily due to higher costs in preparation for the potential launch of z-rostudirsen
Company press release: ID:nGNX6cZhdV
Key Details
Metric |
Beat/Miss |
Actual |
Consensus Estimate |
Q1 EPS |
Beat |
-$0.73 |
-$0.77 (13 Analysts) |
Q1 Net Income |
Slight Miss* |
-$120.85 mln |
-$120.53 mln (11 Analysts) |
Q1 Operating Income |
Slight Miss* |
-$125.28 mln |
-$124.09 mln (11 Analysts) |
Q1 Basic EPS |
|
-$0.73 |
|
Q1 Operating Expenses |
|
$125.28 mln |
|
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.